Antibody

4개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved4 programs
AntibodyLimited DatastaleRochePhase 2

Bendamustine + Rituximab (Bendamustine + Rituximab)

Marginal Zone Lymphoma(MZL) · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 52Status Recruiting
AntibodyLimited DatastaleInternational Extranodal Lympho…Phase 2

Bendamustine and Rituximab (Bendamustine and Rituximab)

Marginal Zone B-cell Lymphoma · Marginal Zone B-cell Lymphoma

#MarginalZoneB-cellLymphoma#Antibody#Phase2#monoclonal-antibody#International
Trials 1Status Active
AntibodyLimited DatastaleThe First Affiliated Hospital w…Phase 2

Zebetuzumab (Zebetuzumab)

Marginal Zone Lymphoma(MZL) · Marginal Zone Lymphoma(MZL)

#MarginalZoneLymphomaMZL#Antibody#Phase2#monoclonal-antibody#The
Trials 1Status Recruiting
AntibodyLimited DatastaleSeoul National University Hospi…Phase 2

bendamustine plus rituximab (bendamustine plus rituximab)

Marginal Zone B-cell Lymphoma · Marginal Zone B-cell Lymphoma

#MarginalZoneB-cellLymphoma#Antibody#Phase2#monoclonal-antibody#Seoul
Trials 1Status Active